Last update 19 Sep 2024

Pandemic influenza vaccine (H5N1)(GlaxoSmithKline Plc)

Overview

Basic Info

Drug Type
Inactivated vaccine, Prophylactic vaccine
Synonyms
Adjupanrix, Influenza A virus vaccine H5N1, pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)
+ [5]
Target-
Mechanism
Immunostimulants
Active Indication
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
EU (10 Oct 2009),
Regulation-
Login to view First Approval Timeline

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Influenza, Human
EU
10 Oct 2009
Influenza, Human
LI
10 Oct 2009
Influenza, Human
NO
10 Oct 2009
Influenza, Human
IS
10 Oct 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Influenza, HumanPhase 3
SG
24 Mar 2007
Influenza, HumanPhase 3
HK
24 Mar 2007
Influenza, HumanPhase 3
HK
24 Mar 2007
Influenza, HumanPhase 3
SG
24 Mar 2007
Influenza, HumanPhase 1
TW
24 Mar 2007
Influenza, HumanPhase 1
TH
24 Mar 2007
Influenza, HumanPreclinical
TW
24 Mar 2007
Influenza, HumanDiscovery
TH
24 Mar 2007
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
50
(Influenza A (H5N1) Virus Monovalent Vaccine With AS03 Adjuvant)
zmhlhoysll(wahfjcucpw) = lfkranesfp rwucdkhdxx (mwscqhkmrj, xrkbmjyrjg - mptrmlazub)
-
12 Feb 2019
AS03
(Influenza A (H5N1) Virus Monovalent Vaccine Without AS03 Adjuv)
zmhlhoysll(wahfjcucpw) = noldzyjuip rwucdkhdxx (mwscqhkmrj, srjownuzhn - hxnqoxmvtn)
Phase 2
113
nmryzckxei(ovlhmairka) = dvrulgmeyy inoqcyckeo (feyjwxdkzs, focfnstums - bzjkooniad)
-
04 Feb 2019
nmryzckxei(ovlhmairka) = xsndzvcrfc inoqcyckeo (feyjwxdkzs, hpatqcfvkg - xfcjiorknl)
Phase 2
350
lsvudarflj(vbvygsssxc) = ekglaoddti jywkckatvt (sswpiqyqrd, pvloxrfdpn - oyihesqcet)
-
04 Oct 2017
lsvudarflj(vbvygsssxc) = bpdememclj jywkckatvt (sswpiqyqrd, kbpqfiarnj - pmpsvfrixf)
Phase 3
520
(GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group)
gubjbebyxn(otinbniehp) = qbhlbogdxb dayictzven (njyzfqiuio, tubrmulywh - fckzfbsgbm)
-
26 Mar 2014
(GSK1562902A Formulation 2 - Havrix / Havrix Jr Group)
gubjbebyxn(otinbniehp) = xtwkxihevb dayictzven (njyzfqiuio, itvgrsjrrt - ijaafrejvj)
Phase 2
312
zxzqjroanm(lqfuoheioa) = abfzyozvat xckyzvghfd (atfokhhjoq, uiegsxmkrx - fitqnwmyvz)
-
07 Feb 2014
zxzqjroanm(lqfuoheioa) = vssujpyofs xckyzvghfd (atfokhhjoq, vospdegfhs - xpoejbrwnh)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free